Details of the Drug
General Information of Drug (ID: DMHNSXP)
Drug Name |
4-chloro-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Chloro-1H-indazole; 13096-96-3; 4-CHLOROINDAZOLE; 1H-Indazole, 4-chloro-; 4-Chloro-2H-indazole; NSC694315; 4-CHLORO(1H)INDAZOLE; CHEMBL246533; MFCD00211065; 4-Chloro-1H-indazole, AldrichCPR; 4-chloro-indazole; zlchem 748; NSC 694315; PubChem21945; AC1Q3RSH; ACMC-1BUW0; AC1L95AW; SCHEMBL476854; 4-Chloro-1H-indazole, 97%; 4-CHLORO (1H)INDAZOLE; CTK0H7106; DTXSID40156818; ZLD0205; CQTGQYVQJOJQCM-UHFFFAOYSA-N; MolPort-001-767-756; 4-CHLORO-3-(1H)INDAZOLE; ACT06078; BCP27008; ZINC5543816; KS-00000O0T; CS-M0440; STL556259; SBB054691; QC-206
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 152.58 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||